Ir directamente a la navegación principal
Ir directamente a la búsqueda
Ir directamente al contenido principal
Pontificia Universidad Javeriana Inicio
Ayuda y preguntas frecuentes
El enlace se abre en una pestaña nueva
Español
English
Buscar contenido en Pontificia Universidad Javeriana
Inicio
Perfiles
Unidades
Productos
Proyectos
Laboratorios y Equipos
Cursos
Actividades
Premios
Medios
Conjuntos de datos
Impacto
Tesis
Immunotherapy of systemic sclerosis
Christina G. Katsiari
, Theodora Simopoulou
,
Ioannis Alexiou
, Lazaros I. Sakkas
Department of Rheumatology and clinical Immunology
University of Thessaly
Producción
:
Contribución a una revista
›
Artículo de revisión
›
revisión exhaustiva
15
Citas (Scopus)
Información general
Huella
Huella
Profundice en los temas de investigación de 'Immunotherapy of systemic sclerosis'. En conjunto forman una huella única.
Clasificar por
Ponderación
Alfabéticamente
Keyphrases
Systemic Sclerosis
100%
Intravenous Immunoglobulin (IVIg)
100%
Tocilizumab
75%
Mycophenolate Mofetil
75%
Cyclophosphamide
75%
Abatacept
75%
Immune Activation
50%
Methotrexate
50%
Rituximab
50%
Belimumab
50%
Microvasculopathy
50%
Fresolimumab
50%
T Cells
25%
High Mortality
25%
B Cells
25%
In Vitro Study
25%
Disease Course
25%
Fibroblasts
25%
Disease Process
25%
Cell-to-cell
25%
Therapeutic Efficacy
25%
Collagen
25%
Lung Function
25%
Hand Function
25%
Internal Organs
25%
Collagen Deposition
25%
Chronic Systemic Disease
25%
Transplant Immunosuppression
25%
Autologous Stem Cell Transplantation (auto-SCT)
25%
Medicine and Dentistry
Systemic Scleroderma
100%
Immunoglobulin
100%
Immunotherapy
100%
Cyclophosphamide
75%
Tocilizumab
75%
Mycophenolate Mofetil
75%
Abatacept
75%
Rituximab
50%
Fresolimumab
50%
Methotrexate
50%
Belimumab
50%
Biological Product
25%
Lung
25%
Disease Course
25%
B Cell
25%
T Cell
25%
In Vitro
25%
Immunosuppressive Treatment
25%
Systemic Disease
25%
Disease Process
25%
Autologous Stem Cell Transplantation
25%
Hand Function
25%
Immunosuppressant
25%
Fibroblast
25%
Immunology and Microbiology
Immunotherapy
100%
Intravenous Immunoglobulin
100%
Systemic Scleroderma
100%
Tocilizumab
75%
Abatacept
75%
Cyclophosphamide
75%
Mycophenolate Mofetil
75%
Rituximab
50%
Methotrexate
50%
Fresolimumab
50%
Belimumab
50%
B Cell
25%
Immunosuppression
25%
Lung
25%
Biological Product
25%
T Cell
25%
Hand Function
25%
Autologous Stem Cell Transplantation
25%
Immunosuppressant
25%
Fibroblast
25%
In Vitro
25%
INIS
immunotherapy
100%
immunoglobulins
100%
diseases
75%
skin
75%
cyclophosphamide
75%
methotrexate
50%
collagen
50%
modifications
25%
deposition
25%
animals
25%
lungs
25%
drugs
25%
mortality
25%
in vitro
25%
organs
25%
hands
25%
stem cells
25%
immunosuppression
25%
fibroblasts
25%